Enochian BioSciences is focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer.
Business Model:
Revenue: $0
Employees: 2-10
Address: 2080 Century Park East, Century City Medical Plaza
City: Los Angeles
State: CA
Zip: 90067
Country: US
Enochian BioSciences is a biotechnology company focusing on VIVA, a Phase III clinical trial for our lead candidate MCV. MCV is an adjuvant immunotherapy that is designed to prevent colon cancer recurrence after standard of care surgery and chemotherapy. MCV, a dendritic cell cancer vaccine, can be used in several solid tumors either as a standalone adjuvant therapy or in combination with checkpoint inhibitors. Our expertise in producing dendritic cells from a patient&s;s blood is combined with conventional production methods with a goal of making new and advanced vaccines for cancer patients.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
6/8/2017
Ticker Symbol:
ENOB
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2021 | Post-IPO Equity | $29M | 12/2018 | Post-IPO Equity | $19M | 9/2016 | Venture Round | - | 9/2016 | Venture Round | - |
---|
Announced Date | Name | Price |
---|---|---|
2/2018 | Enochian Biopharma | |
4/2016 | OncoSynergy |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|